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Background: There has been resurgence in the use of Percutaneous Aortic Balloon
Valvotomy (PABV) in patients at high surgical risk due to development of less
invasive endovascular therapies. We determined the outcomes of concomitant
PABV and percutaneous coronary intervention (PCI) during same hospitalization
and compared them to PABV alone using the nation’s largest hospitalization
database.
Methods: This is a cross-sectional study with time trends using the Nationwide
Inpatient Sample database between the years 1998-2010. We identiﬁed patients
using the International Classiﬁcation of Diseases, 9th Revision, Clinical Modi-
ﬁcation procedure code for valvotomy. Only patients >60 years of age with
aortic stenosis were included. Primary outcome included in-hospital mortality
and secondary outcomes included procedural complications and length of hos-
pital stay
Results: A total of 2,127 PABV procedures were identiﬁed of which 247 were PABV
+ PCI (PABV + PCI group) and 1,880 (weighted N ¼ 9411) were PABVs alone
(PABV group). Majority (69%) of the patients in PABV + PCI group were >80 years
old with equal representation from both genders. The utilization rate of concomitant
PABV + PCI during the same hospitalization has signiﬁcantly increased by 225%
from 5.1% in 1998-1999 to 16.6% in 2009-2010 in US (p < 0.001). Overall in-
hospital mortality rate in the PABV + PCI group was identical to that of the PABV
group (10.3% vs 10.5%). The overall complications rates were also similar in PABV +
PCI vs PABV group (28% vs 29.1%). Patients in the PABV + PCI group had
signiﬁcantly longer stay [median (interquartile range)] in the hospital [7(3-14) vs 5(2-
11) days, p < 0.001) and increased cost of hospitalization [$30,089($21,925 -
$48,267) vs $18,421($11,482 - $32,215), p < 0.001) when compared to those
of PABV group. The signiﬁcant predictors of increased LOS and cost of hospital
admission were unstable condition, occurrence of any complication, weekend
admission and low operator volume.
Conclusions: Concomitant PCI and PABV during the same hospitalization does not
increase in-hospital mortality or complications rate when compared to PABV however
it increases length of hospital stay and cost of hospitalization.TCT-787
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Background: The increased prevalence of transcatheter aortic valve replacement
(TAVR) has brought a renewed interest in the role for balloon aortic valvuloplastyB230 JACC Vol 64/11/Suppl B j September 13–17, 201(BAV) in the management of patients with severe aortic stenosis (AS). The current
study is a prospective study of BAV analyzed by intent-to-treat.
Methods: This is a study of 100 patients undergoing BAV for management of
severe AS. Before the procedure, physicians assigned intent of BAV as 1) bridge to
decision for treatment (BTD); 2) therapeutic bridge to planned therapy (BTX); or
3) palliation (PAL). Patients were followed up to 1 year, with outcomes including
quality of life as measured by the Kansas City Cardiomyopathy Questionnaires
(KCCQ).
Results: Intent in 84 of the planned 100 patients currently enrolled is shown in the
ﬁgure: 62 BTD; 18 BTX; and 4 PAL. 30-day mortality for all patients was 5/84
(6.0%). Two of these patients were in the palliative cohort. Other complications
included cerebrovascular accident 2/84 (2.4%) and acute kidney injury 5/84 (6.0%).
Mean follow-up was 124.091.9 days. Treatment outcomes after BAV are shown
in the ﬁgure. Of all patients surviving to 30 days without having received a
valve (n¼43), summary KCCQ score increased from 40.0922.05 at baseline to
49.4924.04 at 30 days (p¼0.67).
Conclusions: Prior to deﬁnitive treatment, patients saw a non-signiﬁcant improve-
ment in quality of life at 30 days. 61.1% (11/18) BTX patients and 30.6% (19/62)
BTD patients went on to undergo aortic valve replacement. BAV has evolved as a
diagnostic tool to aid in decision-making for TAVR candidacy.Valvular disease - Mitraclip
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Background: Among patients with signiﬁcant functional mitral regurgitation (FMR),
surgery is not always indicated and medical therapy may provide limited relief.
Cardiac resynchronization therapy (CRT) reduces FMR in some but not all patients.
This analysis describes improvements observed following treatment with MitraClip
in high risk FMR patients who were symptomatic despite CRT.
Methods: EVEREST II high risk patients with MR3+ who were NYHA Class III/IV
at study entry despite CRT-D or CRT-P implantation were analyzed. Patients eligible
for MitraClip had left ventricular (LV) dysfunction with LVESD 60 mm and LVEF
20%. One-year outcomes included NYHA Class, Quality of Life (QoL), heart failure
(HF) hospitalizations and echocardiographic measures analyzed by an independent
core lab.
Results: A total of 48 symptomatic high risk FMR patients (mean age 74 yrs) with CRT
underwent theMitraClip procedure. Baseline co-morbidities includedCAD (88%), prior
CV surgery (67%) and moderate-severe renal disease (35%). LVEF pre-MitraClip was
389%. Predicted mortality by STS risk score was 11.57.5%. Observed 30-day
mortalitywas 6%.MR reduction to2+was observed in 78%of CRT patients within 30
days of MitraClip procedure. Despite advanced disease and co-morbidities, 94% were4 j TCT Abstracts/Valvular disease - Aortic: Balloon Aortic Valvuloplasty
